S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Medpace Stock Forecast, Price & News

+3.41 (+2.14 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $162.43
50-Day Range
MA: $148.52
52-Week Range
Now: $162.43
Volume247,737 shs
Average Volume208,904 shs
Market Capitalization$5.80 billion
P/E Ratio49.67
Dividend YieldN/A
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Medpace logo

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:MEDP
Year FoundedN/A



Sales & Book Value

Annual Sales$860.97 million
Cash Flow$4.39 per share
Book Value$20.16 per share


Net Income$100.44 million


Market Cap$5.80 billion
Next Earnings Date4/27/2021 (Estimated)


Overall MarketRank

1.18 out of 5 stars

Medical Sector

871st out of 1,960 stocks

Commercial Physical Research Industry

16th out of 42 stocks

Analyst Opinion: 1.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+3.41 (+2.14 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Medpace stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View analyst ratings for Medpace
or view top-rated stocks.

What stocks does MarketBeat like better than Medpace?

Wall Street analysts have given Medpace a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medpace wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Medpace?

Medpace saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 736,200 shares, a decline of 27.8% from the December 31st total of 1,020,000 shares. Based on an average daily trading volume, of 235,100 shares, the short-interest ratio is currently 3.1 days. Approximately 2.6% of the shares of the company are short sold.
View Medpace's Short Interest

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Medpace

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) posted its earnings results on Sunday, February, 14th. The company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.24 by $0.11. The firm had revenue of $259.68 million for the quarter, compared to analysts' expectations of $246.41 million. Medpace had a net margin of 13.87% and a trailing twelve-month return on equity of 17.67%.
View Medpace's earnings history

How has Medpace's stock price been impacted by COVID-19 (Coronavirus)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 94.2% and is now trading at $162.43.
View which stocks have been most impacted by COVID-19

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY 2021 After-Hours earnings guidance on Monday, February, 15th. The company provided earnings per share (EPS) guidance of 4.08-4.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.17. The company issued revenue guidance of $1.075-1.175 billion, compared to the consensus revenue estimate of $1.1 billion.

What price target have analysts set for MEDP?

5 equities research analysts have issued 12 month price targets for Medpace's stock. Their forecasts range from $75.00 to $180.00. On average, they expect Medpace's share price to reach $121.83 in the next year. This suggests that the stock has a possible downside of 25.0%.
View analysts' price targets for Medpace
or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 65, Pay $592.56k)
  • Mr. Jesse J. Geiger, CFO & COO of Laboratory Operations (Age 47, Pay $418.98k)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 58, Pay $633.22k)
  • Mr. Stephen P. Ewald, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 52, Pay $415.79k)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing
  • Mr. Weimin Gai MS, Sr. VP of Biometrics
  • Mr. Daniel O'Leary, Sr. VP of Medical Department
  • John T. Wynne, Sr. VP of Commercial Operations & Clinical Pharmacology Unit
  • Mr. Kevin M. Brady, Exec. Director of Fin.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.60%), Pendal Group Limited (2.30%), Price T Rowe Associates Inc. MD (2.18%), Renaissance Technologies LLC (1.69%), Dimensional Fund Advisors LP (1.68%) and Fuller & Thaler Asset Management Inc. (1.58%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., Federated Hermes Inc., Charles Schwab Investment Management Inc., Schroder Investment Management Group, JPMorgan Chase & Co., and Barclays PLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace
or view top insider-selling stocks.

Which major investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Rice Hall James & Associates LLC, BlackRock Inc., Canada Pension Plan Investment Board, Boston Trust Walden Corp, Morgan Stanley, Rothschild & Co. Asset Management US Inc., and Wells Fargo & Company MN.
View insider buying and selling activity for Medpace
or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $162.43.

How much money does Medpace make?

Medpace has a market capitalization of $5.80 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 3,400 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

Where are Medpace's headquarters?

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.